Aminoalkylamide substituted cyclohexyl derivatives

A compound selected from the group consisting of

• trans-(4-{2-[(5-Bromo-pyrimidin-2-yl)-methyl-amino]-ethyl}-cyclohexyl)-(4-methyl-[1,4]diazepan-1-yl)-methanone,
• trans-(4-{2-[(5-Bromo-pyrimidin-2-yl)-methyl-amino]-ethyl}-cyclohexyl)-[4-(2-hydroxy-ethyl)-[1,4]diazepan-1-yl]-methanone,
• trans-(4-{2-[(5-Chloro-pyrimidin-2-yl)-methyl-amino]-ethyl}-cyclohexyl)-(4-methyl-[1,4]diazepan-1-yl)-methanone, and
• and pharmaceutically acceptable salts thereof.

A pharmaceutical composition comprising a compound of the formula

• wherein
• U is O or a lone pair;
• R1 is lower-alkyl, hydroxy-lower-alkyl, cycloalkyl or lower-alkyl-NH—C(O)—O-lower-alkyl;
• R2 and R3 are bonded to each other to form a ring together with the N—(CH2)k—N group to which they are attached and —R2—R3—(CH2)3;
• R4 is lower-alkyl;
• R5 is substituted or unsubstituted pyrimidine;
• W is a single bond;
• R6 is hydrogen or lower-alkyl;
• V is a single bond, lower-alkylene, or lower-alkylene-oxy;
• k 2;
• m is 0, 1, 2, or 3, wherein k+m is not more than 5;
• and pharmaceutically acceptable salts thereof
• together with a pharmaceutically acceptable carrier and/or adjuvant.